Alpha Cognition (NASDAQ:ACOG) Raised to “Strong-Buy” at B. Riley Financial

Posted by Brenda Bartman on Aug 21st, 2026

Alpha Cognition (NASDAQ:ACOG – Get Free Report) was upgraded by analysts at B. Riley Financial to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other equities analysts have also weighed in on the company. HC Wainwright lifted their price objective on Alpha Cognition from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Monday. Wall Street Zen raised shares of Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Maxim Group initiated coverage on shares of Alpha Cognition in a report on Friday, May 29th. They issued a “buy” rating and a $12.00 price target on the stock. Craig Hallum reaffirmed a “buy” rating and set a $17.00 price target on shares of Alpha Cognition in a research report on Friday, August 14th. Finally, Raymond James Financial assumed coverage on shares of Alpha Cognition in a research report on Friday, July 10th. They set an “outperform” rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Alpha Cognition presently has a consensus rating of “Buy” and an average price target of $18.00.

Read Our Latest Analysis on Alpha Cognition

Alpha Cognition Trading Up 6.9%

Shares of Alpha Cognition stock opened at $9.50 on Wednesday. Alpha Cognition has a twelve month low of $4.50 and a twelve month high of $10.00. The stock has a market capitalization of $206.91 million, a P/E ratio of -8.64 and a beta of 2.31. The business’s fifty day moving average price is $7.98 and its 200 day moving average price is $6.63.

Alpha Cognition (NASDAQ:ACOG – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.01). The firm had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $4.38 million. Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%. As a group, sell-side analysts predict that Alpha Cognition will post -1.38 EPS for the current year.

Hedge Funds Weigh In On Alpha Cognition

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC acquired a new stake in Alpha Cognition during the 2nd quarter valued at $112,000. Massar Capital Management LP bought a new stake in shares of Alpha Cognition during the 2nd quarter valued at about $116,000. Two Sigma Investments LP bought a new stake in shares of Alpha Cognition during the 3rd quarter valued at about $148,000. Connective Capital Management LLC acquired a new stake in Alpha Cognition during the third quarter worth about $312,000. Finally, ACT Capital Management LLC acquired a new stake in Alpha Cognition during the fourth quarter worth about $335,000.

Alpha Cognition News Summary

Here are the key news stories impacting Alpha Cognition this week:

Positive Sentiment: B. Riley initiated coverage with a Buy rating, highlighting Alpha Cognition’s Alzheimer’s drug opportunity. The new coverage adds to the bullish analyst narrative and supports investor optimism. Alpha Cognition rises as B. Riley initiates at Buy on Alzheimer’s drug
Positive Sentiment: HC Wainwright raised its fourth-quarter 2026 EPS estimate, providing a potentially supportive near-term signal. The firm continues to rate ACOG Buy with a $20 price target, materially above recent trading levels. Alpha Cognition Q4 EPS Estimate Increased by HC Wainwright
Positive Sentiment: HC Wainwright modestly improved its first-quarter 2027 EPS forecast to a loss of $0.12 from a loss of $0.19 and raised its full-year 2027 estimate to a loss of $0.31 from a loss of $0.32. These revisions suggest expectations for improving results beyond 2026.
Neutral Sentiment: HC Wainwright maintained its Buy rating and $20 price target, but its estimates still anticipate continuing losses, including a projected $1.33-per-share loss for fiscal 2026 and a $0.31-per-share loss for fiscal 2027.
Negative Sentiment: The firm lowered several forecasts, including Q3 2026 EPS to a loss of $0.33 from $0.20, Q4 2026 EPS to a loss of $0.25 from $0.20, fiscal 2026 EPS to a loss of $1.33 from $1.08, and Q2 2027 EPS to a loss of $0.13 from $0.10. These cuts underscore ongoing commercialization and profitability risks.

Alpha Cognition Company Profile

(Get Free Report)

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.